ArticleCureus2025
A Single-Center Retrospective Comparative Study of Conventional and Accelerated Fractionated Radiotherapy for Early-Stage Laryngeal Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiotherapy is widely used in the treatment of early-stage laryngeal cancer (stage I and II). We analyzed the efficacy of conventional and accelerated fractionated radiotherapy (52.5 Gy in 16 fractions) for early-stage laryngeal cancer retrospectively. MATERIALS AND
methodsWe compared the outcomes of 25 patients treated with conventional fractionation (CF group: 66-70 Gy in 33-35 fractions) and 20 patients treated with accelerated fractionation (AF group: 52.5 Gy in 16 fractions) radiotherapy from 2011 to 2024 at our institution.
resultsLocal control rate was 87.8% at five years in the CF group and 95% at five years in the AF group. Acute adverse events were significantly higher in the CF group, with 72% Grade 2 or higher dermatitis compared to 20% in the AF group (p < 0.01). No serious late adverse events of Grade 2 or higher were observed in either group. The COVID-19 pandemic increased the use of AF from 34.3% before COVID-19 to 66.7% afterwards, suggesting that AF is a reasonable option as a curative strategy; AF has a shorter overall treatment time (median 22 days), better local control rates, and fewer adverse events.
conclusionAccelerated fractionated radiotherapy of 52.5 Gy in 16 fractions for early-stage laryngeal cancer is a safe and effective option for patients with poor performance status, older age, severe comorbidities, or difficulty with long-term hospital stays, offering a shorter overall treatment time without affecting the cure rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.